Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT05788289 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Start date: March 14, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the combination of tafasitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma.

NCT ID: NCT05788107 Not yet recruiting - Clinical trials for Solid Tumor, Adult Lymphoma

Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma

Start date: June 2023
Phase: Phase 1
Study type: Interventional

This study is a first-in-class open-label phase I human clinical study to evaluate the safety and tolerability of HLX51 with escalated doses in the treatment of patients with advanced/metastatic solid tumors or lymphomas.

NCT ID: NCT05788081 Not yet recruiting - Clinical trials for Follicular Lymphoma Stage III

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD BMS-986369, Rituximab +/- Nivolumab.

TOP-FLOR
Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

First line treatment with combination rituximab and BMS-986369 with, or without nivolumab, in patients in previously untreated Follicular Lymphoma

NCT ID: NCT05786989 Recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma

Start date: February 28, 2023
Phase: Phase 4
Study type: Interventional

The goal of this interventional study is to evaluate efficiency and safety in prior one-line treated diffuse large B-cell lymphoma. The main questions it aims to answer are: - Complete remission rate - Objective remission rate - Progression-free survival - tolerance Participants will recevied a minimum of 2 and a maximum of 6 cycles of R-GemOx(rituximab 375 mg/m2 IV on day 1 , Gemcitabine 1000 mg/m2, Oxaliplatin 100 mg/m2 IV on day 2) and 60 mg selinexor on days 1, 8, and 15 of each cycle

NCT ID: NCT05784987 Not yet recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Start date: April 15, 2023
Phase: N/A
Study type: Interventional

Based on the modified R-MINE of mitoxantrone hydrochloride liposome, the corresponding targeted drug (X) was added according to the genotyping detected by second-generation gene sequencing (NGS) to explore the effectiveness and safety of R-MINE+X in the treatment of recurrent/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

NCT ID: NCT05784441 Not yet recruiting - Clinical trials for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

C-CAR066 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

Start date: July 1, 2023
Phase: Phase 1
Study type: Interventional

The goal of this multicenter study is to test C-CAR066 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: - is C-CAR066 safe and do patients tolerate it well? - what is the best dose of C-CAR066? - will C-CAR066 help patients achieve a response and for how long?

NCT ID: NCT05784415 Recruiting - HIV Infections Clinical Trials

Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell

CS22-03
Start date: April 7, 2022
Phase:
Study type: Observational

This protocol will develop an observational cohort of PLWH who have been or are being treated with CAR19 therapy outside of an AMC clinical trial. Following regulatory approval of this protocol, sites will be asked to capture information of participants, who carry a diagnosis of HIV disease AND received CAR19 therapy outside of a clinical trial between August 30, 2017 and August 31, 2021. Data captured will include data points are available as part of standard of care for participants undergoing CAR19 therapy. AMC investigators, as well as non-AMC investigators will identify eligible participants to the CIBMTR, who in turn will provide the AMC statistical center with de-identified data

NCT ID: NCT05783609 Not yet recruiting - Follicular Lymphoma Clinical Trials

Epcoritamab and Rituximab for First-line Follicular Lymphoma

Start date: July 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: - Rituximab (a type of monoclonal antibody therapy) - Epcoritamab (a T-cell bispecific antibody)

NCT ID: NCT05783596 Not yet recruiting - Follicular Lymphoma Clinical Trials

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Start date: July 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: - Glofitamab (a type of immunotherapy) - Obinutuzumab (a type of immunotherapy)

NCT ID: NCT05779930 Not yet recruiting - Clinical trials for Acute Lymphoblastic Leukemia, in Relapse

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

Start date: April 2023
Phase: Early Phase 1
Study type: Interventional

This pilot study examines the safety and efficacy of anti-CD19 CAR T cells manufactured on-site in children and young adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin lymphoma. Patients will undergo screening, leukapheresis (cell collection), lymphodepleting chemotherapy with fludarabine and cyclophosphamide, followed by the anti-CD19 CAR T cell infusion. The lymphodepleting chemotherapy is administered over four days IV to prepare the body for the CAR T cells. The anti-CD19 CAR-T cells are infused between 2-14 days after the last dose of chemotherapy. This study is designed for participants to begin lymphodepleting chemotherapy during the CAR T cell manufacture and receive a fresh cell infusion on the day that manufacturing is complete. Some patients may need more time in between the cell collection and the CAR T cell infusion, therefore, the cells may be manufactured and frozen prior to administration. Patients will be followed for a year after the cell infusion on the study and for up to 15 years to monitor for potential long term side effects of cell therapy.